BCM
SPRY icon

Bridgeway Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Bridgeway Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,944
Closed -$134K – 1419
2023
Q2 		$134K Hold
19,944
– – ﹤0.01% 1212
2023
Q1 		$130K Sell
19,944
-69,500
-78% -$534K ﹤0.01% 1186
2022
Q4 		$763K Sell
89,444
-6,700
-7% -$43.5K 0.02% 794
2022
Q3 		$508K Buy
96,144
+30,344
+46% +$150K 0.01% 890
2022
Q2 		$279K Sell
65,800
-36,900
-36% -$129K 0.01% 1012
2022
Q1 		$360K Buy
+102,700
New +$447K 0.01% 1024

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bridgeway Capital Management's SPRY Position: Q3 2023 in Review

Bridgeway Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2023, closing a stake of 19,944 shares — an estimated $134K sold.

Bridgeway Capital Management first reported a position in SPRY in Q1 2022 and held it in 6 quarters. The position peaked at $763K in Q4 2022. 97 funds tracked by Wall St. Rank hold SPRY as of Q3 2023.

  • Bridgeway Capital Management reported no remaining ARS Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 19,944 ARS Pharmaceuticals shares in Q3 2023, an estimated $134K.
  • Bridgeway Capital Management first reported a position in ARS Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Bridgeway Capital Management's ARS Pharmaceuticals position peaked at $763K in Q4 2022.
  • 97 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.